近畿大学ライフサイエンス研究所Kindai University Life Science Research Institute

平成25年度

巻頭言

平成25年度
ライフサイエンス研究所紀要発刊によせて
前研究所長（平成26年10月1日の人事異動により）
楠　進（医学部内科学教室神経内科学部門教授、前医学部長）

　ライフサイエンス研究所は近畿大学本部直轄の組織で、医学部からは独立した研究施設ですが、医学部の建物内にあり、機器備品およびほとんどの教員、技術員が医学部共同研究施設と共有、共同兼任の状態にあることから、医学部の研究に寄与するところが大きな施設といえるでしょう。
　私立大学医学部や私立医科大学で基礎的な研究に専念する医学部出身者は元来多くありませんでしたが、新臨床研修医制度の導入で母校の医学部に残る卒業生自体が減少し、研究を志向する若い医師は非常に少なくなってきました。私どものライフサイエンス研究所も研究者不足、若い医師の研究志向の低下の影響をうけていると考えられます。
　しかし、時間も研究費も潤沢とはいえない中で、多くの質の高い研究成果が発表されたことは、誠に喜ばしいことと考えます。基礎系および臨床系の多くの教室の多大な御尽力と、研究所の技術員の奮闘に敬意を表するとともに、引き続いての御協力をお願いする次第です。

平成25年度ライフサイエンス研究所紀要

免疫学教室（宮澤 正顯　教授）

  1. Infection of adult thymus with murine retrovirus induces virus-specific central tolerance that prevents functional memory CD8+ T cell differentiation. Takamura S, Kajiwara E, Tsuji-Kawahara S, Masumoto T, Fujisawa M, Kato M, Chikaishi T, Kawasaki Y, Kinoshita S, Itoi M, Sakaguchi N, Miyazawa M. PLoS Pathog. 2014 Mar 20;10(3):e1003937.
  2. Elimination of friend retrovirus in the absence of CD8+ T cells. Tsuji-Kawahara S, Miyazawa M. J Virol. 2014 Feb;88(3):1854-5.
  3. Differential requirements of cellular and humoral immune responses for Fv2-associated resistance to erythroleukemia and for regulation of retrovirus-induced myeloid leukemia development. Tsuji-Kawahara S1, Kawabata H, Matsukuma H, Kinoshita S, Chikaishi T, Sakamoto M, Kawasaki Y, Miyazawa M. J Virol. 2013 Dec;87(24):13760-74.
  4. IFN-γ-producing effector CD8 T lymphocytes cause immune glomerular injury by recognizing antigen presented as immune complex on target tissue. Tsumiyama K, Hashiramoto A, Takimoto M, Tsuji-Kawahara S, Miyazawa M, Shiozawa S. J Immunol. 2013 Jul 1;191(1):91-6.

公衆衛生学教室（伊木　雅之　教授）

  1. Trabecular bone score (TBS) predicts vertebral fractures in Japanese women over 10 years independently of bone density and prevalent vertebral deformity: the Japanese Population-Based Osteoporosis (JPOS) cohort study. Iki M, Tamaki J, Kadowaki E, Sato Y, Dongmei N, Winzenrieth R, Kagamimori S, Kagawa Y, Yoneshima H. J Bone Miner Res. 2014 Feb;29(2):399-407.
  2. Growth-related disappearance of the childhood relationship between height and blood pressure levels. Fujita Y, Kouda K, Nakamura H, Nishio N, Takeuchi H, Iki M. Ann Hum Biol. 2014 Jan-Feb;41(1):91-3.
  3. Renal function and bone mineral density in community-dwelling elderly Japanese men: the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study. Fujita Y, Iki M, Tamaki J, Kouda K, Yura A, Kadowaki E, Sato Y, Moon JS, Tomioka K, Okamoto N, Kurumatani N. Bone. 2013 Sep;56(1):61-6.
  4. Vitamin D status and body fat measured by dual-energy X-ray absorptiometry in a general population of Japanese children. Kouda K, Nakamura H, Fujita Y, Ohara K, Iki M. Nutrition. 2013 Oct;29(10):1204-8.
  5. Association between depressive symptoms and metabolic syndrome in Japanese community-dwelling older people: a cross-sectional analysis from the baseline results of the Fujiwara-kyo prospective cohort study. Morikawa M1, Okamoto N, Kiuchi K, Tomioka K, Iwamoto J, Harano A, Saeki K, Fukusumi M, Hashimoto K, Amano N, Hazaki K, Yanagi M, Iki M, Yamada F, Kishimoto T, Kurumatani N. Int J Geriatr Psychiatry. 2013 Dec;28(12):1251-9.
  6. Association of rapid weight gain during early childhood with cardiovascular risk factors in Japanese adolescents. Fujita Y, Kouda K, Nakamura H, Iki M. J Epidemiol. 2013;23(2):103-8.

ゲノム生物学教室（西尾　和人　教授）

  1. Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer. Kimura H, Ohira T, Uchida O, Matsubayashi J, Shimizu S, Nagao T, Ikeda N, Nishio K. Lung Cancer. 2014 Mar;83(3):329-33.
  2. The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer. Hayashi H, Arao T, Togashi Y, Kato H, Fujita Y, De Velasco MA, Kimura H, Matsumoto K, Tanaka K, Okamoto I, Ito A, Yamada Y, Nakagawa K, Nishio K. Oncogene. 2013 Dec 23. [Epub ahead of print]
  3. Novel single nucleotide polymorphism markers for low dose aspirin-associated small bowel bleeding. Shiotani A, Murao T, Fujita Y, Fujimura Y, Sakakibara T, Nishio K, Haruma K. PLoS One. 2013 Dec 18;8(12):e84244.
  4. The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile. Fujita H, Miyadera K, Kato M, Fujioka Y, Ochiiwa H, Huang J, Ito K, Aoyagi Y, Takenaka T, Suzuki T, Ito S, Hashimoto A, Suefuji T, Egami K, Kazuno H, Suda Y, Nishio K, Yonekura K. Mol Cancer Ther. 2013 Dec;12(12):2685-96.
  5. EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFRT790M mutation. Yamada T, Azuma K, Muta E, Kim J, Sugawara S, Zhang GL, Matsueda S, Kasama-Kawaguchi Y, Yamashita Y, Yamashita T, Nishio K, Itoh K, Hoshino T, Sasada T. PLoS One. 2013 Nov 5;8(11):e78389.
  6. Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma. Kawakami H, Okamoto I, Terao K, Sakai K, Suzuki M, Ueda S, Tanaka K, Kuwata K, Morita Y, Ono K, Nishio K, Nishimura Y, Doi K, Nakagawa K. Cancer Med. 2013 Dec;2(6):933-41.
  7. A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors. Okamoto W, Yoshino T, Takahashi T, Okamoto I, Ueda S, Tsuya A, Boku N, Nishio K, Fukuoka M, Yamamoto N, Nakagawa K. Cancer Chemother Pharmacol. 2013 Nov;72(5):1063-71.
  8. LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, Shahidi M, Yamamoto N. J Clin Oncol. 2013 Sep 20;31(27):3335-41.
  9. Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. Nishio M, Horai T, Horiike A, Nokihara H, Yamamoto N, Takahashi T, Murakami H, Yamamoto N, Koizumi F, Nishio K, Yusa W, Koyama N, Tamura T. Br J Cancer. 2013 Aug 6;109(3):538-44.
  10. Overexpression of heparan sulfate 6-O-sulfotransferase-2 in colorectal cancer. Hatabe S, Kimura H, Arao T, Kato H, Hayashi H, Nagai T, Matsumoto K, DE Velasco M, Fujita Y, Yamanouchi G, Fukushima M, Yamada Y, Ito A5 Okuno K1, Nishio K. Mol Clin Oncol. 2013 Sep;1(5):845-850.
  11. Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor. Sakai K, Horiike A, Irwin DL, Kudo K, Fujita Y, Tanimoto A, Sakatani T, Saito R, Kaburaki K, Yanagitani N, Ohyanagi F, Nishio M, Nishio K. Cancer Sci. 2013 Sep;104(9):1198-204.
  12. Influence of novel supramolecular substance, [2] rotaxane, on the caspase signaling pathway in melanoma and colon cancer cells in vitro. Hara K, Beppu T, Kimura M, Fujita Y, Takata T, Nishio K, Ono N. J Pharmacol Sci. 2013;122(2):153-7.
  13. A microarray-based gene expression analysis to identify diagnostic biomarkers for unknown primary cancer. Kurahashi I, Fujita Y, Arao T, Kurata T, Koh Y, Sakai K, Matsumoto K, Tanioka M, Takeda K, Takiguchi Y, Yamamoto N, Tsuya A, Matsubara N, Mukai H, Minami H, Chayahara N, Yamanaka Y, Miwa K, Takahashi S, Takahashi S, Nakagawa K, Nishio K. PLoS One. 2013 May 9;8(5):e63249.
  14. SOX4 is a direct target gene of FRA-2 and induces expression of HDAC8 in adult T-cell leukemia/lymphoma. Higuchi T, Nakayama T, Arao T, Nishio K, Yoshie O. Blood. 2013 May 2;121(18):3640-9.
  15. Slug increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin in lung cancer cells. Tamura D, Arao T, Nagai T, Kaneda H, Aomatsu K, Fujita Y, Matsumoto K, De Velasco MA, Kato H, Hayashi H, Yoshida S, Kimura H, Maniwa Y, Nishio W, Sakai Y, Ohbayashi C, Kotani Y, Nishimura Y, Nishio K. Cancer Med. 2013 Apr;2(2):144-54.

archive

近畿大学
近畿大学医学部

Copyright (C) Kindai University Life Science Research Institute All rights reserved.